CML

(redirected from Chronic myelogenous leukemia)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

CML

Capital Market Line

In the capital asset pricing model, a line that plots the extra return an investor expects for each change in the level of risk. Rational investors expect higher returns for riskier assets and the capital market line shows this graphically. A portfolio that accurately reflects the capital market line is considered a Markowitz efficient portfolio. The slope of the capital market line is a calculation of the equilibrium market price of risk. See also: Beta.
References in periodicals archive ?
Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Chronic Myelogenous Leukemia (CML) Therapeutics therapeutics market.
Prognostic study of alpha-interferon (INF)-treated chronic myelogenous leukemia (CML) patients: II.
The data we presented today show that the VAL-083's unique mechanism of action could be an important new therapeutic to treat glioblastoma, chronic myelogenous leukemia and non-small cell lung cancer, where chemotherapy resistance remains a significant unmet clinical need.
Table 61: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Diagnosis Percentage by Age Group, 2004-2008 82
The company has four drug programs in clinical development: INNO-406, Tamibarotene, INNO-206, and INNO-305, for the treatment of chronic myelogenous leukemia, acute promyelocytic leukemia, small cell lung cancer, and acute myelogenous leukemia, respectively.
The report provides information on the key drivers and challenges of the Chronic Myelogenous Leukemia (CML) Therapeutics market.
The genetic abnormality in chronic myelogenous leukemia isn't inherited.
STI-571 targets a mutant protein in a cancer-causing gene specific to chronic myelogenous leukemia, a cancer of the blood that strikes more than 4,300 Americans each year.
OTCBB:IVPH) announced data that the company believes supports further development of its drug candidates, INNO-406, an orally bioavailable dual Bcr-Abl and Lyn-kinase inhibitor for Gleevec resistant or intolerant chronic myelogenous leukemia, and INNO-305, a peptide immunotherapy for the treatment of acute myelogenous leukemia, will be presented at the American Society of Hematology (ASH) 49th Annual Meeting and Exposition.
23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the leukemia market will be driven mostly by chronic myelogenous leukemia (CML) therapies (Novartis's Gleevec and Tasigna and Bristol-Myers Squibb's Sprycel) and chronic lymphocytic leukemia (CLL) therapies (Biogen Idec/Roche's Rituxan and Cephalon's Treanda) until 2015, when patent and orphan-drug exclusivities of key brands will impact the sustainability of this growth.
More than 10 years ago, as a Walnut High School sophomore, Anissa was diagnosed with chronic myelogenous leukemia.
After treating the young woman's cancer, chronic myelogenous leukemia, with radiation and chemotherapy that destroyed her bone marrow and its crucial supply of stem cells, the physicians attempted to restore the marrow by injecting into their patient a few ounces of the thawed cord blood.

Full browser ?